Uncertainty surrounding the permanent FDA commissioner nomination stems from the May 2026 transition after Commissioner Marty Makary's departure, leaving Kyle Diamantas as acting commissioner with day-to-day authority over agency operations and the Human Foods Program. Trader consensus shows a tight contest because the White House continues vetting multiple candidates amid Senate confirmation requirements, while administration priorities include regulatory reforms that could influence selection. Diamantas holds an edge from incumbency and staff relationships, yet the 32.6% probability of no announcement by December 31 reflects procedural timelines, potential holds, and the absence of a confirmed front-runner. Developments such as formal nominations, hearings, or shifts in health policy directives could quickly alter probabilities.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoKyle Diamantas 13%
Brett Giroir 8.3%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Wol.
$18,953 Wol.
Dec 31, 2026
Kyle Diamantas
28%
Stephen Hahn
6%
Brett Giroir
8%
Grace Graham
4%
Sara Brenner
7%
No announcement by December 31
33%
Kyle Diamantas 13%
Brett Giroir 8.3%
Sara Brenner 7.2%
Stephen Hahn 6.2%
$18,953 Wol.
$18,953 Wol.
Dec 31, 2026
Kyle Diamantas
$6,163 Wol.
28%
Stephen Hahn
$1,802 Wol.
6%
Brett Giroir
$3,007 Wol.
8%
Grace Graham
$4,151 Wol.
4%
Sara Brenner
$2,798 Wol.
7%
No announcement by December 31
$1,032 Wol.
33%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Uncertainty surrounding the permanent FDA commissioner nomination stems from the May 2026 transition after Commissioner Marty Makary's departure, leaving Kyle Diamantas as acting commissioner with day-to-day authority over agency operations and the Human Foods Program. Trader consensus shows a tight contest because the White House continues vetting multiple candidates amid Senate confirmation requirements, while administration priorities include regulatory reforms that could influence selection. Diamantas holds an edge from incumbency and staff relationships, yet the 32.6% probability of no announcement by December 31 reflects procedural timelines, potential holds, and the absence of a confirmed front-runner. Developments such as formal nominations, hearings, or shifts in health policy directives could quickly alter probabilities.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Rynek otwarty: May 12, 2026, 7:59 PM ET
Wolumen
$18,953Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Uncertainty surrounding the permanent FDA commissioner nomination stems from the May 2026 transition after Commissioner Marty Makary's departure, leaving Kyle Diamantas as acting commissioner with day-to-day authority over agency operations and the Human Foods Program. Trader consensus shows a tight contest because the White House continues vetting multiple candidates amid Senate confirmation requirements, while administration priorities include regulatory reforms that could influence selection. Diamantas holds an edge from incumbency and staff relationships, yet the 32.6% probability of no announcement by December 31 reflects procedural timelines, potential holds, and the absence of a confirmed front-runner. Developments such as formal nominations, hearings, or shifts in health policy directives could quickly alter probabilities.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Wolumen
$18,953Data zakończenia
Dec 31, 2026Rynek otwarty
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Uncertainty surrounding the permanent FDA commissioner nomination stems from the May 2026 transition after Commissioner Marty Makary's departure, leaving Kyle Diamantas as acting commissioner with day-to-day authority over agency operations and the Human Foods Program. Trader consensus shows a tight contest because the White House continues vetting multiple candidates amid Senate confirmation requirements, while administration priorities include regulatory reforms that could influence selection. Diamantas holds an edge from incumbency and staff relationships, yet the 32.6% probability of no announcement by December 31 reflects procedural timelines, potential holds, and the absence of a confirmed front-runner. Developments such as formal nominations, hearings, or shifts in health policy directives could quickly alter probabilities.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania